Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.

Biomarker studies have shown that expression of the T-cell coregulatory ligand PDL1 on tumor cells correlates with clinical responsiveness to the PD1 antibody nivolumab. Here, we report the findings of a preclinical cancer vaccine study demonstrating vaccine-dependent PDL1 upregulation in the tumor microenvironment. We formulated an IFNγ-inducing cancer vaccine called TEGVAX that combined GM-CSF and multiple Toll-like receptor agonists to increase the number of activated dendritic cells. Treatment of established tumors with TEGVAX retarded tumor growth in a manner associated with enhanced systemic antitumor immunity. Unexpectedly, TEGVAX also upregulated PDL1 expression in the tumor microenvironment, possibly explaining why tumors were not eliminated completely. In support of this likelihood, PDL1 upregulation in this setting relied upon IFNγ-expressing tumor-infiltrating CD4(+) and CD8(+) T cells and administration of a PD1-blocking antibody with TEGVAX elicited complete regression of established tumors. Taken together, our findings provide a mechanistic rationale to combine IFNγ-inducing cancer vaccines with immune checkpoint blockade.

[1]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[2]  David J Mooney,et al.  In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice , 2009, Science Translational Medicine.

[3]  M. Moskalenko,et al.  Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies. , 2009, Clinical immunology.

[4]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. L. Calhoon.  Immune therapy of cancer. , 1988, The Journal of the Oklahoma State Medical Association.

[6]  P. Klenerman,et al.  Immune surveillance against a solid tumor fails because of immunological ignorance. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H. Lyerly,et al.  CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapy , 2007, Expert opinion on biological therapy.

[9]  G. Zhu,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[10]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[11]  Michael H. Smith,et al.  Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults , 2003, Antimicrobial Agents and Chemotherapy.

[12]  N. Van Rooijen,et al.  Simultaneous Targeting of Toll- and Nod-Like Receptors Induces Effective Tumor-Specific Immune Responses , 2012, Science Translational Medicine.

[13]  J. Bulte,et al.  Magnetovaccination as a novel method to assess and quantify dendritic cell tumor antigen capture and delivery to lymph nodes. , 2009, Cancer research.

[14]  Magdalini Moutaftsi,et al.  Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant , 2011, PloS one.

[15]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[16]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[17]  S. Reed,et al.  Adjuvants for cancer vaccines. , 2010, Seminars in immunology.

[18]  R. Zheng,et al.  Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. , 2008, Cancer research.

[19]  D. Pardoll,et al.  Synergistic Effect of a Granulocyte-Macrophage Colony-Stimulating Factor–Transduced Tumor Vaccine and Systemic Interleukin-2 in the Treatment of Murine Colorectal Cancer Hepatic Metastases , 2003, Annals of Surgical Oncology.

[20]  G. Freeman,et al.  Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. , 2013, Cancer research.

[21]  M. Salgaller.  American Association for Cancer Research , 2000, Expert opinion on investigational drugs.

[22]  J. Farrar,et al.  Feasibility trial of electro-acupuncture for aromatase inhibitor related arthralgia in breast cancer survivors. , 2009 .

[23]  R. Steinman,et al.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor , 1992, The Journal of experimental medicine.

[24]  C. Drake,et al.  Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. , 2012, Current opinion in immunology.

[25]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[26]  A. Qattan,et al.  The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. , 2006, Neoplasia.

[27]  M. Tomayko,et al.  Determination of subcutaneous tumor size in athymic (nude) mice , 2004, Cancer Chemotherapy and Pharmacology.

[28]  T. Whiteside,et al.  Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. , 2009, Cancer research.

[29]  S. Bertholet,et al.  A Synthetic Adjuvant to Enhance and Expand Immune Responses to Influenza Vaccines , 2010, PloS one.

[30]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[31]  S. Choi,et al.  Water-dispersible ferrimagnetic iron oxide nanocubes with extremely high r₂ relaxivity for highly sensitive in vivo MRI of tumors. , 2012, Nano letters.

[32]  H. Sugerman,et al.  Association between Incident Cancer and Subsequent Stroke , 2015, Annals of neurology.

[33]  D. Pardoll,et al.  Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. , 2006, Cancer research.

[34]  Tasuku Honjo,et al.  PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.

[35]  S. Akira,et al.  Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis , 2008, Proceedings of the National Academy of Sciences.

[36]  Irah L. King,et al.  GM-CSF–dependent, CD103+ dermal dendritic cells play a critical role in Th effector cell differentiation after subcutaneous immunization , 2010, The Journal of experimental medicine.

[37]  D. Pardoll,et al.  Intratumoral Administration of TLR4 Agonist Absorbed into a Cellular Vector Improves Antitumor Responses , 2011, Clinical Cancer Research.

[38]  T. Kopp,et al.  Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells , 2007, The Journal of experimental medicine.

[39]  M. Azuma,et al.  Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.

[40]  Jason B. Williams,et al.  Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells , 2013, Science Translational Medicine.

[41]  R. Weichselbaum,et al.  Induced sensitization of tumor stroma leads to eradication of established cancer by T cells , 2007, The Journal of experimental medicine.

[42]  S. Reed,et al.  GLA-SE, a synthetic toll-like receptor 4 agonist, enhances T-cell responses to influenza vaccine in older adults. , 2012, The Journal of infectious diseases.

[43]  B. Czerniecki,et al.  Effect of multiple activation stimuli on the generation of Th1-polarizing dendritic cells. , 2011, Human immunology.

[44]  S. Ferrone,et al.  Abstract 632: Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing , 2014 .

[45]  J. Allison,et al.  PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors , 2010, Proceedings of the National Academy of Sciences.

[46]  References , 1971 .

[47]  S. Tyring,et al.  Resiquimod: a new immune response modifier with potential as a vaccine adjuvant for Th1 immune responses. , 2004, Antiviral research.

[48]  E. Jaffee,et al.  Genetically Engineered Tumor Cell Vaccine in a Head and Neck Cancer Model , 2003, The Laryngoscope.

[49]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.